What question did this study set out to answer?

This analysis aims to characterize bleeding risks in patients with antiphospholipid syndrome receiving anticoagulant therapy.

December 8, 2025BloodOpen Access

Characterization and risk factors of anticoagulation-related bleeding in patients with thrombotic antiphospholipid syndrome: An analysis using a synthetic real-world data platform

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals anticoagulant therapy and anemia increase major bleeding risk in venous thromboembolism patients with antiphospholipid syndrome.

This analysis aims to characterize bleeding risks in patients with antiphospholipid syndrome receiving anticoagulant therapy.
Utilized the MDClone platform to analyze data from APS patients with venous thromboembolism (VTE) between 2018-2025.
Included patients with at least one outpatient anticoagulant prescription and a follow-up of six months or more.
Defined bleeding using ISTH criteria and evaluated risk factors through multivariate logistic regression.
Among 451 APS patients, major bleeding occurred in 9.5% and clinically relevant non-major bleeding in 28.8%.
Independent risk factors for major bleeding included warfarin use (OR 2.67), anemia (OR 3.37), female sex (OR 2.28), and liver disease (OR 1.89).
No correlation was found between antiphospholipid antibody profiles and increased bleeding risk.

Mahmoud et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis reveals anticoagulant therapy and anemia increase major bleeding risk in venous thromboembolism patients with antiphospholipid syndrome.